Capsaicin 8%

DRUG3 trials

Sponsors

NeurogesX, Astellas Pharma Inc, Averitas Pharma, Inc.

Conditions

Diabetic Peripheral NeuropathyPainPainful Diabetic NeuropathyPeripheral Diabetic NeuropathyPostherpetic Neuralgia

Phase 2

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

CompletedNCT00916942

NeurogesXPostherpetic Neuralgia

Start: 2009-06-30End: 2009-07-31Target: 20Updated: 2009-09-09

Phase 3

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

CompletedNCT01533428

Astellas Pharma IncDiabetic Peripheral Neuropathy, Pain

Start: 2012-02-29End: 2014-02-28Updated: 2015-11-04

Unknown Phase

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Active, not recruitingNCT06495424

Averitas Pharma, Inc.Painful Diabetic Neuropathy, Peripheral Diabetic Neuropathy

Start: 2025-03-14End: 2027-03-01Updated: 2026-07-13

Related Papers

Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia.

2011-12-1921 citations